Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma

Autor: Maartje W. Rohaan, Troels H. Borch, Joost H. van den Berg, Özcan Met, Rob Kessels, Marnix H. Geukes Foppen, Joachim Stoltenborg Granhøj, Bastiaan Nuijen, Cynthia Nijenhuis, Inge Jedema, Maaike van Zon, Saskia Scheij, Jos H. Beijnen, Marten Hansen, Carlijn Voermans, Inge M. Noringriis, Tine J. Monberg, Rikke B. Holmstroem, Lidwina D.V. Wever, Marloes van Dijk, Lindsay G. Grijpink-Ongering, Ludy H.M. Valkenet, Alejandro Torres Acosta, Matthias Karger, Jessica S.W. Borgers, Renske M.T. ten Ham, Valesca P. Retèl, Wim H. van Harten, Ferry Lalezari, Harm van Tinteren, Astrid A.M. van der Veldt, Geke A.P. Hospers, Marion A.M. Stevense-den Boer, Karijn P.M. Suijkerbuijk, Maureen J.B. Aarts, Djura Piersma, Alfons J.M. van den Eertwegh, Jan-Willem B. de Groot, Gerard Vreugdenhil, Ellen Kapiteijn, Marye J. Boers-Sonderen, W. Edward Fiets, Franchette W.P.J. van den Berkmortel, Eva Ellebaek, Lisbet R. Hölmich, Alexander C.J. van Akkooi, Winan J. van Houdt, Michel W.J.M. Wouters, Johannes V. van Thienen, Christian U. Blank, Aafke Meerveld-Eggink, Sebastian Klobuch, Sofie Wilgenhof, Ton N. Schumacher, Marco Donia, Inge Marie Svane, John B.A.G. Haanen

Publikováno v: New England Journal of Medicine, 387(23), 2113-2125. MASSACHUSETTS MEDICAL SOC
The New England Journal of Medicine, 387, 2113-2125
New England journal of medicine, 387(23), 2113-2125. Massachussetts Medical Society
Rohaan, M W, Borch, T H, Van Den Berg, J H, Met, Ö, Kessels, R, Geukes Foppen, M H, Stoltenborg Granhøj, J, Nuijen, B, Nijenhuis, C, Jedema, I, Van Zon, M, Scheij, S, Beijnen, J H, Hansen, M, Voermans, C, Noringriis, I M, Monberg, T J, Holmstroem, R B, Wever, L D V, Van Dijk, M, Grijpink-Ongering, L G, Valkenet, L H M, Torres Acosta, A, Karger, M, Borgers, J S W, Ten Ham, R M T, Retèl, V P, Van Harten, W H, Lalezari, F, Van Tinteren, H, Van Der Veldt, A A M, Hospers, G A P, Stevense-Den Boer, M A M, Suijkerbuijk, K P M, Aarts, M J B, Piersma, D, Van Den Eertwegh, A J M, De Groot, J W B, Vreugdenhil, G, Kapiteijn, E, Boers-Sonderen, M J, Fiets, W E, Van Den Berkmortel, F W P J, Ellebaek, E, Hölmich, L R, Van Akkooi, A C J, Van Houdt, W J, Wouters, M W J M, Van Thienen, J V, Blank, C U, Meerveld-Eggink, A, Klobuch, S, Wilgenhof, S, Schumacher, T N, Donia, M, Svane, I M & Haanen, J B A G 2022, ' Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma. ', New England Journal of Medicine, vol. 387, no. 23, pp. 2113-2125 . https://doi.org/10.1056/NEJMoa2210233
The New England journal of medicine, 387(23), 2113-2125. Massachussetts Medical Society
New England Journal of Medicine, 387(23), 2113-2125. MASSACHUSETTS MEDICAL SOCIETY
The New England Journal of Medicine, 387, 23, pp. 2113-2125

Item does not contain fulltext BACKGROUND: Immune checkpoint inhibitors and targeted therapies have dramatically improved outcomes in patients with advanced melanoma, but approximately half these patients will not have a durable benefit. Phase 1-2 tr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edf28a71e5a16116e2b0f59cdac9485a
https://research.rug.nl/en/publications/9033fdbd-9e6f-4cca-a35b-50890da9f292

Vemurafenib-Induced Toxic Epidermal Necrolysis: An Emerging Adverse Event

Autor: Ana Filipe Monteiro, Margarida Rato, César Martins

Publikováno v: Revista da Sociedade Portuguesa de Dermatologia e Venereologia, Vol 76, Iss 3 (2018)

Vemurafenib, a selective inhibitor of the BRAF V600 mutation, is Food and Drug Administration and European Medicines Agency approved for the treatment of stage IV metastatic melanoma alone or in combination. Among the adverse effects, cutaneous toxic

Externí odkaz: https://doaj.org/article/860454b9ecab4c77b91fb5c961f3cc37

Melanoma models for the next generation of therapies

Autor: Ze'ev Ronai, Leonard I. Zon, Carmit Levy, Meenhard Herlyn, Marcus Bosenberg, Amanda W. Lund, David B. Lombard, Jean-Christophe Marine, Richard M. White, Yardena Samuels, Charles K. Kaufman, Christin E. Burd, Shaheen Khan, Marc Hurlbert, Kristen L. Mueller, Eleonora Leucci, Andrew E. Aplin, Sheri L. Holmen, Iwei Yeh, Ashani T. Weeraratna, David J. Adams, Martin McMahon, Corine Bertolotto, Florian A. Karreth, Sebastian Kobold, Glenn Merlino, Carla Daniela Robles-Espinoza, Ping Chi, Jessie Villanueva, Niroshana Anandasabapathy, Kerrie L. Marie, Maria S. Soengas, Jiyue Zhu, Richard Marais, Craig J. Ceol, E. Elizabeth Patton

Publikováno v: Patton, E E, Mueller, K L, Adams, D J, Anandasabapathy, N, Aplin, A E, Bertolotto, C, Bosenberg, M, Ceol, C, Chi, P, Herlyn, M, Holmen, S L, Karreth, F A, Kaufman, C, Khan, S, Kobold, S, Leucci, E, Levy, C, Lombard, D B, Lund, A W, Marie, K L, Marine, J-C, Marais, R, McMahon, M, Robles-Espinoza, C D, Ronai, Z A, Samuels, Y, Soengas, M S, Villanueva, J, Weeraratna, A T, White, R M, Yeh, I, Zhu, J, Zon, L I, Hurlbert, M S & Merlino, G 2021, ' Melanoma Models for the Next Generation of Therapies ', Cancer Cell . https://doi.org/10.1016/j.ccell.2021.01.011
Cancer Cell
Patton, E E, Mueller, K L, Adams, D J, Anandasabapathy, N, Aplin, A E, Bertolotto, C, Bosenberg, M, Ceol, C J, Burd, C E, Chi, P, Herlyn, M, Holmen, S L, Karreth, F A, Kaufman, C K, Khan, S, Kobold, S, Leucci, E, Levy, C, Lombard, D B, Lund, A W, Marie, K L, Marine, J-C, Marais, R, McMahon, M, Robles-Espinoza, C D, Ronai, Z A, Samuels, Y, Soengas, M S, Villanueva, J, Weeraratna, A T, White, R M, Yeh, I, Zhu, J, Zon, L I, Hurlbert, M S & Merlino, G 2021, ' Melanoma models for the next generation of therapies ', Cancer Cell, vol. 39, no. 5, pp. 610-631 . https://doi.org/10.1016/j.ccell.2021.01.011

Summary There is a lack of appropriate melanoma models that can be used to evaluate the efficacy of novel therapeutic modalities. Here, we discuss the current state of the art of melanoma models including genetically engineered mouse, patient-derived

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9caa7c8db82a369339ccaae359006a1d
https://doi.org/10.1016/j.ccell.2021.01.011

Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade

Autor: Carlos Gomez-Roca, Philippe Cassier, Dmitriy Zamarin, Jean-Pascal Machiels, Jose Luis Perez Gracia, F Stephen Hodi, Alvaro Taus, Maria Martinez Garcia, Valentina Boni, Joseph P Eder, Navid Hafez, Ryan Sullivan, David Mcdermott, Stephane Champiat, Sandrine Aspeslagh, Catherine Terret, Anna-Maria Jegg, Wolfgang Jacob, Michael A Cannarile, Carola Ries, Konstanty Korski, Francesca Michielin, Randolph Christen, Galina Babitzki, Carl Watson, Georgina Meneses-Lorente, Martin Weisser, Dominik Rüttinger, Jean-Pierre Delord, Aurelien Marabelle

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol. 10, no.5, p. e004076 (2022)

BackgroundThis phase 1b study (NCT02323191) evaluated the safety, antitumor activity, pharmacokinetics, and pharmacodynamics of colony-stimulating factor-1 receptor-blocking monoclonal antibody (mAb) emactuzumab in combination with the programmed cel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2c2dc4accf632390ea464a967fc522a
https://pubmed.ncbi.nlm.nih.gov/35577503

Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma

Autor: Karla A. Lee, Andrew Maltez Thomas, Laura A. Bolte, Johannes R. Björk, Laura Kist de Ruijter, Federica Armanini, Francesco Asnicar, Aitor Blanco-Miguez, Ruth Board, Neus Calbet-Llopart, Lisa Derosa, Nathalie Dhomen, Kelly Brooks, Mark Harland, Mark Harries, Emily R. Leeming, Paul Lorigan, Paolo Manghi, Richard Marais, Julia Newton-Bishop, Luigi Nezi, Federica Pinto, Miriam Potrony, Susana Puig, Patricio Serra-Bellver, Heather M. Shaw, Sabrina Tamburini, Sara Valpione, Amrita Vijay, Levi Waldron, Laurence Zitvogel, Moreno Zolfo, Elisabeth G. E. de Vries, Paul Nathan, Rudolf S. N. Fehrmann, Véronique Bataille, Geke A. P. Hospers, Tim D. Spector, Rinse K. Weersma, Nicola Segata

Publikováno v: Nature Medicine
Lee, K A, Thomas, A M, Bolte, L A, Björk, J R, de Ruijter, L K, Armanini, F, Asnicar, F, Blanco-Miguez, A, Board, R, Calbet-Llopart, N, Derosa, L, Dhomen, N, Brooks, K, Harland, M, Harries, M, Leeming, E R, Lorigan, P, Manghi, P, Marais, R, Newton-Bishop, J, Nezi, L, Pinto, F, Potrony, M, Puig, S, Serra-Bellver, P, Shaw, H M, Tamburini, S, Valpione, S, Vijay, A, Waldron, L, Zitvogel, L, Zolfo, M, de Vries, E G E, Nathan, P, Fehrmann, R S N, Bataille, V, Hospers, G A P, Spector, T D, Weersma, R K & Segata, N 2022, ' Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma ', Nature Medicine, vol. 28, no. 3, pp. 535-544 . https://doi.org/10.1038/s41591-022-01695-5
Nature Medicine, 28. Nature Publishing Group

The composition of the gut microbiome has been associated with clinical responses to immune checkpoint inhibitor (ICI) treatment, but there is limited consensus on the specific microbiome characteristics linked to the clinical benefits of ICIs. We pe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14d9010bfaf4e6f5e7f69e6b0bbaca17